Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis

Karakonstantis, Stamatis; Rousaki, Maria; Vassilopoulou, Loukia; Kritsotakis, Evangelos I.

doi:10.1016/j.cmi.2023.08.029

Cited by 30 publications

(9 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since pneumonia and other pulmonary infections and complications are commonly seen in the ICU department that enforce toward applying mechanical ventilators and other respiratory procedures, which in turn increases the risk of acquiring the infection [28], hence more than twothirds (69%) of the isolates in this study were collected from respiratory samples, which agrees with previous studies [36,37].…”

Section: Discussionsupporting

confidence: 88%

Virulence Molecular Epidemiology of Clinical Carbapenem-Resistant Acinetobacter baumannii: First Report from Jordan

Zueter,

Al Balawi,

Al-Tamimi

et al. 2024

Preprint

View full text Add to dashboard Cite

1) Background: carbapenem-resistant Acinetobacter baumannii (CRAB) is an opportunistic Gram-negative pathogen that has a significant role in healthcare-associated infections. Unlike several studies on the antibiotic-resistant epidemiology of A. baumanni, virulence molecular epidemiology was less studied. This study aimed to investigate CRAB virulence genes and their ability to form biofilms, and to correlate their biofilm formation ability with both; biofilm-encoding virulence genes and carbapenemase-encoding resistance genes. 2) Methods: 107 CRAB clinical isolates were collected from two hospitals in Jordan between 2018 and 2019 and were screened for virulence genes using PCR. In addition, biofilm formation ability was assessed using the microtiter plate method. 3) Results: the frequencies of the bap, OmpA, surA, PLD, paaE, basD, and traT virulence genes were 99.10%, 98.20%, 98.20%, 95.50%, 89.10%, 86.40%, and 8.20%, respectively. Overall, 86.4% of the tested isolates were biofilm formers with varying degrees; weak (28.2%), moderate (36.4%) and strong (21.8%). A significant relationship was found between the carbapenemase-encoding gene (OXA-23 gene) and biofilm production. 4) Conclusion: to the best of our knowledge, this is the first study in Jordan that inspected CRAB virulence genes and highlighted the importance of improving infection control measures to avoid CRAB outbreaks.

show abstract

Section: Discussionsupporting

confidence: 88%

Virulence Molecular Epidemiology of Clinical Carbapenem-Resistant Acinetobacter baumannii: First Report from Jordan

Zueter,

Al Balawi,

Al-Tamimi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Although mutations that diminish cefiderocol efficacy occur, resistance remains rare among systemic isolates of P. aeruginosa . 43 , 44 , 45 Studies to evaluate the frequency of resistance development in ocular models are warranted. Penetration of antibiotics into the cornea can be a barrier for antibiotic efficacy, 35 , 46 and although this study demonstrated reductions of bacteria injected into the cornea, the rabbits were young and work with larger subjects may help to address this issue.…”

Section: Discussionmentioning

confidence: 99%

Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis

Romanowski,

Mumper,

Shanks

et al. 2024

Ophthalmology Science

View full text Add to dashboard Cite

“…Unfortunately, cefiderocol and sulbactam/durlobactam are not yet widely available. Furthermore, sulbactam/durlobactam is not active against metallo-β-lactamase producing A. baumannii, which, in combination with the high prevalence of cefiderocol nonsusceptibility in these strains [66,67], could prove to be a problem in the future. As these new antibiotics are increasingly being used in clinical practice, there is a risk of selection and spread of New Dehli Metallo-beta-lactamase (NDM)-producing A. baumannii, which is already increasingly being reported [68,69].…”

Section: Available Treatments Of a Baumannii Colistin Resistancementioning

confidence: 99%

Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections

Papazachariou,

Tziolos,

Karakonstantis

et al. 2024

Antibiotics

Self Cite

View full text Add to dashboard Cite

Acinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly due to the development of resistance to multiple antibiotics, including colistin, one of the last-resort treatments. This review highlights all the possible mechanisms of colistin resistance and the genetic basis contributing to this resistance, such as modifications to lipopolysaccharide or lipid A structures, alterations in outer membrane permeability via porins and heteroresistance. In light of this escalating threat, the review also evaluates available treatment options. The development of new antibiotics (cefiderocol, sulbactam/durlobactam) although not available everywhere, and the use of various combinations and synergistic drug combinations (including two or more of the following: a polymyxin, ampicillin/sulbactam, carbapenems, fosfomycin, tigecycline/minocycline, a rifamycin, and aminoglycosides) are discussed in the context of overcoming colistin resistance of A. baumannii infections. Although most studied combinations are polymyxin-based combinations, non-polymyxin-based combinations have been emerging as promising options. However, clinical data remain limited and continued investigation is essential to determine optimal therapeutic strategies against colistin-resistant A. baumannii.

show abstract

Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis

Cited by 30 publications

References 88 publications

Virulence Molecular Epidemiology of Clinical Carbapenem-Resistant Acinetobacter baumannii: First Report from Jordan

Virulence Molecular Epidemiology of Clinical Carbapenem-Resistant Acinetobacter baumannii: First Report from Jordan

Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis

Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections

Contact Info

Product

Resources

About